CPT code 55875 covers the placement of needles or catheters into the prostate for subsequent placement of radioactive seeds (prostate brachytherapy). This procedure, performed by urologists or oncologists, is a key component of definitive or adjuvant localized prostate cancer treatment and has implications for procedural coding, facility billing, and multidisciplinary care coordination nationwide. Major payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.

Readers will find a concise explanation of the clinical service represented by 55875, typical sites of service, and the reasons the code matters for national billing and coverage practices. The publication summarizes payer coverage patterns and billing considerations, highlights common reporting scenarios (including inclusion of concurrent cystoscopy), and provides benchmarks and policy updates relevant to clinicians, coding professionals, and health system administrators. The content also outlines the clinical context for prostate seed implantation and identifies areas where coding clarity influences reimbursement and documentation workflows.